The takeaway
Viemed Healthcare Inc shows a moderate seasonal pattern over 8 years of data — strongest in January (+1.4%) and softest in September (−3.9%).
Right now
In July, the stock has risen 50% of years, averaging +4.7%, about +2.6 pts better than the S&P 500.
The full picture
Viemed Healthcare Inc's most dependable month has been January, higher in 6 of 8 years; September has been its least reliable, up just 38% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 |
Month by month
The stock's clearest edge over the S&P 500 lands in April (+8.6 pts); it has trailed the market most in December (−4.6 pts).
“vs S&P” is Viemed Healthcare Inc’s average for a month minus the S&P 500’s average for that same month — isolating Viemed Healthcare Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, January has closed higher 80% of the time versus 75% across the last 8 years — the pattern is weakening.
Figures are the typical (median) January return and how often it rose — the last 5 years versus the last 8(the heatmap’s default window). This verdict stays anchored to that 8-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Dependability is the through-line here. January stands out, higher in 6 of 8 Januaries, but it heads a clutch of months that pull the year reliably upward.
Its average (+1.4%) and median (+4.2%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. That reliability comes with real swings, mind — even January ranges by 10.7% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: January has cleared the S&P 500 by +1.6 points above the index. That consistency sets it apart from the field, where the average stock manages January only about 53% of the time.
The strength clusters rather than stands alone — January–April forms a firm stretch that carries much of the year. The weaker half of the year is plainer: September has been the soft spot — the weakest of 2 months that average a loss (−3.9%), and the edge isn't year-round — the stock has trailed the S&P 500 in December, September, and November. Its roughest month on record was a −25.1% August in 2022 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, January's last five years slipping below its longer-run record.
The takeaway is less about when to buy than what to expect: January aside, the stock's months offer little reliable tilt. With a short 8-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (January), its worst (September), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2018 its best month (January, +1.4%) has run well ahead of its worst (September, −3.9%) — the heatmap above shows how steady that gap has been year to year.
January has been the strongest, averaging +1.4% and closing higher in 6 of 8 years since 2018.
It's the weakest, averaging −3.9% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade